Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Arcutis Biotherapeutics (ARQT) Receivables - Net (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Receivables - Net data on record, last reported at $146.2 million in Q4 2025.

  • For Q4 2025, Receivables - Net rose 100.13% year-over-year to $146.2 million; the TTM value through Dec 2025 reached $146.2 million, up 100.13%, while the annual FY2025 figure was $146.2 million, 100.13% up from the prior year.
  • Receivables - Net reached $146.2 million in Q4 2025 per ARQT's latest filing, up from $115.1 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $146.2 million in Q4 2025 and bottomed at $2.4 million in Q3 2022.
  • Average Receivables - Net over 4 years is $53.8 million, with a median of $40.3 million recorded in 2024.
  • Peak YoY movement for Receivables - Net: skyrocketed 698.72% in 2023, then soared 91.48% in 2025.
  • A 4-year view of Receivables - Net shows it stood at $8.5 million in 2022, then soared by 205.12% to $25.8 million in 2023, then skyrocketed by 183.12% to $73.1 million in 2024, then surged by 100.13% to $146.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $146.2 million in Q4 2025, $115.1 million in Q3 2025, and $106.7 million in Q2 2025.